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duration and left bundle branch block (LBBB) morphol-
ogy. Therefore, only LBBB morphology represents a class 
I indication for CRT, whereas non-LBBB morphology was 
downgraded to a class IIa (QRS > 150 ms) and IIb indication 
(QRS 120–150 ms), respectively [5].
This re-evaluation was backed up by the results of the 
long-term follow-up of the MADIT-CRT study which 
revealed an improved prognosis solely for patients with 
LBBB, whereas the prognosis for patients with non-LBBB 
was worsened [6]. Non-LBBB is associated with a con-
glomeration of diverse causes which might also show delay 
in left ventricular wall activation.
This dilemma is obvious: On the one hand there are many 
heart failure patients with non-LBBB who are at the end of 
the road for medical therapy and urgently need further treat-
ment options. On the other hand, we need some certainty that 
we do not harm these patients by implanting a CRT-D system.
The guidelines concerning implantation of CRT-D in 
patients with non-LBBB are reflective of this dilemma. 
They advise us to implant these patients only after careful 
selection. However, they do not tell us how to select [4].
This represents the value of the article from the Maas-
tricht Group. By demonstrating the feasibility of coronary 
venous electroanatomical mapping, they break new ground 
in proposing an individualised method of screening patients 
with non-LBBB for eligibility for CRT implantation, which 
might one day be part of the selection process.
In their study they draw the conclusion that neither QRS 
duration nor morphology are adequate discriminators for 
the selection process, already hinting that this selection 
might not be an easy one.
Likewise they consistently demonstrate that the lat-
est activation region was consistently at the basal lateral 
wall, which raises a couple of questions which need to be 
answered in further systematic studies:
With their article published in this issue of the Journal, Stip-
donk and colleagues touch on a subject bearing significant 
clinical implications [1].
The inception of the concept of electrical cardiac resyn-
chronisation therapy (CRT) was followed by an unprec-
edented clinical success story for heart failure patients 
suffering from bundle branch block. Initially we embraced 
this concept for all patients with long QRS duration inde-
pendent of the morphology of the bundle branch block [2, 
3]. As in all therapies, there were some non-responders; 
however, for a highly invasive therapy this was unaccept-
ably high at 30–40 %. Therefore considerable efforts have 
been put into echocardiography to improve patient selec-
tion as well as optimise atrioventricular and interventricular 
stimulation patterns.
These echocardiographic studies revealed that also 
patients with smaller QRS durations might suffer from 
delayed left ventricular wall activation leading to another 
multicentre study feeding the aspiration to further expand 
the indication for CRT. However, the higher the rise, the 
greater the fall. Consecutive studies painstakingly showed 
that CRT therapy might not only be ineffective but actually 
detrimental for the patients [4].
In the present guidelines, echocardiographic parameters 
for left ventricular activation delay are irrelevant for the 
CRT indication. Meta-analysis of the landmark CRT stud-
ies displays a dependency of the responder rate on QRS 
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1. Do we really have to target our stimulation at the lat-
est point of activation? This question is so important 
as it influences the way we interpret an electrical map-
ping which often displays a rather homogenous spread 
of activation with the last 10 or 20 % of the map being 
activated very slowly. This is also closely related to the 
question how epicardial and endocardial mapping cor-
relate, which seems close according to our own experi-
ence. Basal stimulation at a point where the coronary 
venous anatomy is still rather broad would be challeng-
ing and implies a call for the more frequent use of quad-
ripolar or mechanically fixable electrodes which, due to 
their special pre-specified form, would allow easier po-
sitioning of an electrode in this target region. Therefore, 
the question has to be answered as to whether stimulat-
ing at this point yields haemodynamic benefit or if it 
is not sufficient to target some point where 80 or 90 % 
homogenous activation has passed and is located less 
basally. This brings up the next question:
2. Does our electroanatomical activation correlate to our 
haemodynamic activation? There are some promising 
studies showing a correlation when comparing electrode 
delays, but further substantiating the above study is a 
sine qua non for further use of this method and it brings 
up the final and all-dominant question:
3. Will heart failure patients with non-LBBB selected for 
and implanted according to individualised electroana-
tomical mapping show clinical benefit in the furnace of 
a randomised clinical trial?
There is a lot of a fascinating and exciting but also sobering 
and disillusioning road ahead to be filled with studies like 
the above, to form the pieces of a puzzle which some day 
might yield the whole picture, allowing us to finally answer 
the question if and how to implant these patients.
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